ClinicalTrials.gg
Not yet recruitingNCT07389018PROSPER-SYDEUpdated Nov 17, 2026

Study to Evaluate the Feasibility of Syde® Digital Endpoints for Monitoring Patients With Progressive Supranuclear Palsy - Richardson Syndrome (PSP-R)

An observational study in Progressive Supranuclear Palsy- Richardson Syndrome (PSP-R), sponsored by SYSNAV. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by SYSNAV · Observational

How we know

Updated Nov 17, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Supranuclear Palsy, Progressive with a site in France — 6 open to participants now, 6 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · France.

Started
2027
the only one that year
Observational
6 of 22
3 open now
Registered
20th of 22
by date

Among the 22 studies in Supranuclear Palsy, Progressive with a site in France, this one is the only one that started in 2027, is one of 6 observational ones, and was the 20th registered.

Supranuclear Palsy, Progressive

171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.

Browse Supranuclear Palsy, Progressive studies →

Open to participants now

6 of the 22 studies in Supranuclear Palsy, Progressive with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Supranuclear Palsy, Progressive with a site in France, or all of them as a file.
02

Study summary

The study aims to assess the feasibility/acceptability of real-world activity monitoring by the Syde® wearable device in PSP-R. The Syde® collected data will be compared to on-site conventional clinical endpoints, including functional capacity and cognitive assessments, as well as core scales assessments.

03

Conditions studied

  • Progressive Supranuclear Palsy- Richardson Syndrome (PSP-R)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients With Progressive Supranuclear Palsy - Richardson Syndrome (PSP-R)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.18 years old or older

2.Participants affiliated to, or beneficiary from, a social security.

3.Ambulant patients (i.e. able to walk 10 meters without assistance)

4.Signed form by the patient himself or, by caregivers if the patient is not capable to fill, date and sign the form due to fine motor function difficulties..

5.Possible or probable PSP-R according to MDS criteria 2017(Hoglinger et al., Mov Disorder, 2017).

Exclusion criteria

Exclusion Criteria:

  1. Patients with extreme cognitive disorders that limit their understanding of the data collection process (training of device use and 4-week recording periods every 4 months, device return at the end of the study), tests to be performed including eye movement recording (every 8 months), the implication of the study and consent.
  2. Patients who do not tolerate to keep the sensors on their ankles.
  3. Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the lower limbs.
  4. A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion.
  5. Patients affected by any other disorder having a significant impact on gait or lower limb function.
  6. Participant covered by a legal protection measure (guardianship, curatorship or safeguarding of justice) or who is unable to express their consent.
  7. Absence of caregiver.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of patients reaching the optimal threshold of recordings during the recording periods defined in the protocol.

    Number of patients reaching the optimal threshold of recordings during the recording periods defined in the protocol (supposed optimal threshold for analysis) at baseline, Month 4, Month 8, Month 12 and Month 16.

    Time frame: 16 months

  2. French Usability score (F-SUS) at Month 4 and at the end of the study

    Usability score at Month 4 and Month 16. The System Usability Scale is a 10-item questionnaire . It is a simple tool to measure the usability of an interactive system and it is widely used. For each item, the user is asked to express their level of agreement or disagreement from 1 (strongly disagree) and 5 (strongly agree).

    Time frame: 16 months

Secondary outcomes

  1. Change from baseline in the total wearing time at months 4, 8, 12, and 16.

    Change from baseline in the total wearing time at months 4, 8, 12, and 16.

    Time frame: 16 months

  2. Reproducibility of Syde® digital endpoints for each recording period timepoint

    Reproducibility of Syde® digital endpoints assessed by the ICC (Intra-Class Correlation) and Bland and Altman analysis for each recording period timepoint (baseline, 4 months, 8 months, 12 months, and 16 months)

    Time frame: 16 months

  3. Correlation between Syde® digital endpoints and 2-minute walk test (2MWT)

    Correlation at baseline and at different timepoints between Syde® digital endpoints and 2MWT

    Time frame: 16 months

  4. Correlation between Syde® digital endpoints and 10-meter walk test (10MWT)

    Correlation at baseline and at different timepoints between Syde® digital endpoints and 10MWT

    Time frame: 16 months

  5. Correlation between Syde® digital endpoints and Timed Up and Go (TUG)

    Correlation at baseline and at different timepoints between Syde® digital endpoints and TUG

    Time frame: 16 months

  6. Correlation between Syde® digital endpoints and falls reported by the participants

    Correlation at baseline and at different timepoints between Syde® digital endpoints and falls reported by the participants

    Time frame: 16 months

  7. Correlation between Syde® digital endpoints and Progressive Supranuclear Palsy Rating Scale (PSP-RS)

    Correlation at baseline and at different timepoints between Syde® digital endpoints and PSP-RS

    Time frame: 16 months

  8. Correlation between Syde® digital endpoints and Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS)

    Correlation at baseline and at different timepoints between Syde® digital endpoints and PSP-CDS

    Time frame: 16 months

  9. Correlation between Syde® digital endpoints and Montreal Cognitive Assessment (MoCA)

    Correlation at baseline and at different timepoints between Syde® digital endpoints and MoCA

    Time frame: 16 months

  10. Longitudinal change in Syde® digital endpoints. The Syde® digital endpoints will include the SV95C (Stride Velocity 95th centile)

    Change from baseline in Syde® digital endpoints at 4, 8, 12 and 16 months. The Syde® digital endpoints will include the SV95C (Stride Velocity 95th centile)

    Time frame: 16 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Nov 2028, 22 months later.

Of 37 observational studies under Supranuclear Palsy, Progressive, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 54. This study's planned 22 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start May 2026 → Jan 2027, primary completion Mar 2028 → Nov 2028 and completion Mar 2028 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 5, 2026
StartEst.
Jan 2027was May 2026
Primary completionEst.
Nov 2028was Mar 2028
CompletionEst.
Nov 2028was Mar 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 2026→Jan 2027
Nov 17, 2026
Primary completion
Mar 2028→Nov 2028
Nov 17, 2026
Study completion
Mar 2028→Nov 2028
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date May 2026→Jan 2027
    Primary completion Mar 2028→Nov 2028
    Study completion Mar 2028→Nov 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07389018
Lead sponsor
SYSNAV
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Jan 2027 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Ferial Toumi
Contact
ferial.toumi@sysnav.fr
+33 2 78 00 10 98
Jean-Philippe BRANDEL
principal investigator · Hopital Fondation Adolphe de Rothschild

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion